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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effectiveness and safety of physical activity promotion and exercise training interventions in individuals with congenital
heart disease.
B A C K G R O U N D
Due to improved medical interventions children with complex
congenital heart disease (ConHD) are now living into adulthood,
presenting new challenges for health care professionals as this pop-
ulation is now at risk of acquiring non-communicable ‘lifestyle’
diseases (NCDs) (Giannakoulas 2009; Khairy 2010). It has been
reported that people with ConHD fail to meet the minimum
requirements for physical activity (Reybrouck 2005; McCrindle
2007); and that the prevalence of obesity is increasing (Andonian
2019). This significantly increases the chance of developingNCDs
such as coronary heart disease, type II diabetes mellitus, and breast
and colon cancers (Lee 2012). Patients with ConHD also have
reduced cardiorespiratory fitness (CRF) (Amedro 2017); this has
been significantly linked with mortality and surgical outcomes in
this population (Inuzuka 2012; d’Udekem 2017). It is crucial,
therefore, that people with ConHD increase their physical activ-
ity in line with the current guidelines of 60 minutes of moderate
to vigorous physical activity (MVPA) daily for young people and
150 minutes of MVPA weekly in adults (Department of Health
2011). However, there is currently no consensus on how best to
improve physical activity and physical fitness for all ages and dis-
ease severities in people with ConHD. The aim of this review is
to collate and summarise the randomised controlled trial evidence
for physical activity promotion and exercise training interventions
in people with ConHD.
Description of the condition
ConHD is a developmental abnormality of the heart or intratho-
racic vessels (or both) and can include both structural and electri-
cal abnormalities of the heart (Mitchell 1971). The pathophysiol-
ogy is complex, from shunting lesions to single ventricles - for a
three-part review see Rhodes 2008, Sommer 2008a and Sommer
2008b. The birth prevalence of ConHD has been stable for over
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a decade, plateauing around 9.1 in every 1000 live births (95%
confidence interval (CI) 9.00 to 9.20). As a result, each year 1.35
million children are born with ConHD globally (van der Linde
2011). Medical innovation has cut infant mortality significantly:
in 1987/88 over 30% of ConHD mortality was in children aged
less than four years old; in 2004/05 this had fallen to less than
10%, with the highest proportion of deaths occurring in geriatrics
(Khairy 2010). This has led to a significant shift in the prevalence
of ConHD in adulthood: in 2010 it was estimated that adults ac-
counted for two-thirds of the ConHD population (Marelli 2014).
Pregnant women with ConHD are six times more likely to die
during labour (OR6.7, 95%CI 2.9 to 15.4); and their children are
at an increased risk of inheriting ConHD (Blue 2012; Opotowsky
2012).
People with ConHD suffer reduced life expectancy, which can
be primarily attributed to cardiac sequelae such as progressive
heart failure and sudden cardiac death (Zomer 2012; Diller 2015).
Health-related quality of life for those with ConHD has been
reported as lower compared to healthy controls, specifically in
the domains of physical functioning and general health (Gratz
2009; Dulfer 2013). Furthermore, CRF is impaired in children
and adults with ConHD, with large heterogeneity both within a
condition and between different conditions of ConHD (Kempny
2011; Diller 2015). CRF also declines more steeply throughout
childhood and adolescence compared with age-matched controls,
which may have implications for adults as lower fitness levels
have been linked to a poorer prognosis (Amedro 2017; d’Udekem
2017). Fortunately, regular physical activity, such as a 10-week
walking programme, has been shown to improve CRF, physical
activity and quality of life in this population (Dua 2010).
Description of the intervention
Physical activity consists of any bodily movement involving skele-
tal muscles that results in an increased energy expenditure, whereas
exercise training is a planned and structured period of physical
activity with the intention to maintain or improve physical fit-
ness components (Caspersen 1985). Although MVPA guidelines
exist for healthy adults, children and adolescents (Department of
Health 2011), there are no national or international MVPA guide-
lines for people with ConHD. However, a recommendation by
the American Heart Association supports an active lifestyle and
use of recreational sports and exercise training to enhance the lives
of children and adult ConHD patients (Longmuir 2013). Impor-
tantly the risks of exercise in an adult ConHD population have
been well documented but not at a paediatric level. In a study of
25,790 adults with ConHD, a total of 1189 deaths were reported
with only 17 (0.01%) patients dying of sudden cardiac death of ar-
rhythmic origin during physical activity (Koyak 2012). This high-
lights the relative safety of physical activity in this population.
How the intervention might work
Physical functioning is a domain of health-related quality of life
and can be defined as limitations in mobility activities, such as
walking specifieddistances. Physical functioninghas been reported
to be lower in people with ConHD compared to healthy con-
trols (Gratz 2009). By increasing a patient’s cardiorespiratory or
muscular fitness, or both, an intervention may improve self-re-
ported physical functioning as patients will be able to undertake
daily activitiesmore efficiently (Gratz 2009). The use of cardiopul-
monary exercise testing (CPET), using different exercise modal-
ities (running, cycling) and measuring oxygen uptake and mus-
cular strength testing, are both practical and accurate assessments
of physical functioning. We may include less objective measures,
such as the 6-minute walk test and multistage fitness test, within
the review if there is a lack of ’gold standard’ testing, but we will
analyse the data separately. Self-reported physical functioning can
be assessed using validated questionnaires, examples of which are
provided later in this protocol. We will consider both objectively
measured and self-reported physical functioning in our review.
Physical activity and exercise training have been shown to have
direct benefits at the molecular level on skeletal muscle, the en-
dothelium and the myocardium. Muscle fibre adaptations, mito-
chondrial activity, stem cell proliferation and an increase in ni-
tric oxide bioavailability are just some positive molecular adapta-
tions seen after exercise training (Adams 2017). These underlying
mechanisms are proposed to contribute to increased health-related
quality of life, exercise capacity and a decrease in morbidity and
mortality (Adams 2017).
Why it is important to do this review
Physical fitness is known to be lower in people with ConHD and
deteriorates with age faster compared to healthy people (Kempny
2011; Amedro 2017). This has significant implications as CRF
is predictive of medium-term mortality rates (Inuzuka 2012),
and is considered the most important factor in determining a
positive outcome post surgical intervention (Fontan procedure)
(d’Udekem 2017).
Currently there is a dearth of evidence to adequately inform what
should be the optimal physical activity and exercise interventions
for peoplewithConHD(Gomes-Neto2016).Consequently, exer-
cise is not adequately discussed in paediatric cardiac clinics; this is
primarily attributed to a lack of training and knowledge of the cur-
rent exercise recommendations for people withConHD (Williams
2017). We hope by conducting this review to inform health care
policy and highlight future avenues for research for those afflicted
by a heart condition.
O B J E C T I V E S
2Physical activity interventions for people with congenital heart disease (Protocol)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
To assess the effectiveness and safety of physical activity promotion
and exercise training interventions in individuals with congenital
heart disease.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (with individual patient allocation,
cluster allocation, or cross-over design) that compare physical ac-
tivity promotion or exercise training intervention to a ’no physical
activity/no exercise’ comparator. We will include trials irrespective
of their duration of follow-up and we will include studies reported
as full text, those published as abstract only, and unpublished data.
Types of participants
All individuals, irrespective of age and sex, with or without surgi-
cal or catheter procedures, with a diagnosis of ConHD, who are
deemed by the trial investigators as suitable for participation in
physical activity or an exercise training intervention. In a situation
where a trial contains a mixed population (i.e. individuals with
ConHD and other heart disease diagnoses) we will (1) assess if
the subgroup results in ConHD are reported, and if not we will
contact the authors; and if results are not available then (2) we will
include all the trial data so long as the population with ConHD
makes up 50% or more of the total population.
Types of interventions
All interventions - structured or unstructured, supervised or un-
supervised - that include physical activity promotion or exercise
training, delivered in any setting (community, hospital/outpatient
centre and at home). So long as they are considered suitable for
physical activity all individuals with ConHD, regardless of age,
previous catheter or surgical intervention, are eligible for the in-
tervention. Cardiac rehabilitation (CR) would be considered ex-
ercise-based only if it includes some form of exercise training or
physical activity promotion intervention.Wewill consider all exer-
cise-based CR interventions either given alone or as part of a more
comprehensive CR programme that has education and psycholog-
ical components. The intervention can be based in any setting(s),
for example at home, in the community, in primary, secondary
and tertiary care. Furthermore, interventions can be supervised or
unsupervised and single or multi-component. Interventions will
need to be adjusted for age, maturity and disease status for those
patients participating. The intervention will be compared to no
physical activity control or physical activity as usual.
Both the intervention and control group participants will receive
usual medical care as reported by the study. Usual care typically
comprises regular check-ups, drug treatment as required and de-
pendent on congenital heart disease status, and general advice for
a healthy and active lifestyle. We anticipate most studies will pro-
vide usual care; however, where a study does not provide standard
care we will not exclude it from the review as this may be because
of a trial being conducted in a less economically developed region,
where there is no provision for usual care. Physical activity restric-
tions may be required, dependent on the type of congenital heart
disease.
Types of outcome measures
For us to include them, studies should have intended to assess any
of the outcomes in both the intervention and the control groups.
We will extract outcomes at all time points and we will categorise
as up to 6 months; 6 to 12 months; and longer than 12 months at
follow-up. As long-term follow-up (> 12 months) is our period of
most interest, due to its usefulness in influencing policy decisions,
we will include this follow-up period in the ‘Summary of findings’
table.Wewill seek the following primary and secondary outcomes,
but they will not form the basis of inclusion/exclusion criteria for
the review.
Primary outcomes
1. Health-related quality of life determined by a validated
questionnaire
2. Maximal cardiorespiratory fitness (CRF)
3. Device-worn ‘objective’ measures of physical activity
Secondary outcomes
1. Validated questionnaire-based ‘subjective’ measures of
physical activity
2. Return to work or full-time education
3. Hospital admissions
4. Sub-maximal CRF
5. Muscular strength determined by:
◦ grip strength
◦ isokinetic testing
◦ muscular endurance capacity
6. Adverse events
We anticipate there will be a substantial variability in the reported
outcome measures; we will approach this as follows.
Health-related quality of life (HRQoL)
There is large variability in the HRQoL scales used in studies fo-
cusing on people with ConHD and these include but are not lim-
ited to: the Child Health Questionnaire, Pediatric Quality of Life
Inventory, Congenital Heart Disease-TNO/AZL Adult Quality
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of Life, Child Quality of Life Questionnaire, EQ-5D and the 36-
Item Short Form Health Survey (Dulfer 2017). If the question-
naire reported is validated, we will pool all studies’ HRQoL data
and analyse accordingly.
Maximal cardiorespiratory fitness (CRF)
Recent research has reported that a supramaximal bout after an in-
cremental cardiopulmonary exercise test verifies maximal oxygen
consumption (VO max) in nearly 90% of cases in both chil-
dren and adolescents (Sansum 2019). We will therefore pool both
peak VO and VO max assessed by cardiopulmonary exercise
testing on a treadmill or cycle ergometer, as we expect a dearth of
objectively measured CPET data to be reported. We will report
other validated cardiorespiratory fitness tests, such as the multi-
stage fitness test, but we will not pool these into the main analysis
but will analyse and report them separately.
Device-worn measures of physical activity
We will pool for one analysis all ’movement’ data collected from
either accelerometers (Actigraph,GENEACTIV) and smart watch
devices (Polar, Garmin). We will analyse heart rate data separately
from movement data, but again we will pool all data from heart
rate devices - portable electrocardiography to smart watches - into
the same analyses.
Questionnaire-based measures of physical activity
We will include and analyse in one analysis all validated question-
naires that have physical activity components, such as the General
Practice Physical ActivityQuestionnaire (GPPAQ) and theGlobal
Physical Activity Questionnaire (GPAQ).
Hospital admissions
We will assess hospital admission based on the number of people
with at least one admissionduring a study’s follow-up.The purpose
of this is to reduce the impact of outpatient appointments or
unrelated admissions (or both) skewing the data.
Sub-maximal CRF
We note that it has been suggested that ’anaerobic threshold’ (if
calculated according to ventilation parameters) should be super-
seded by the term ’gas exchange threshold’ (Jones 2005), and we
will not count anaerobic threshold (AT) and the gas exchange
threshold (GET) as two separate outcomes. The task of determin-
ing abnormal and normal is very difficult because of the paucity of
the reference or normative database. The issue here is confidence
in the maximal test to determine cardiorespiratory fitness. The
criteria will not be different for children compared to adults.
Muscular strength
Grip strength, isokinetic testing and muscular endurance capac-
ity are our key suboutcomes of muscular fitness. We will analyse
and report all within the report separately but only include grip
strength within the ’Summary of findings’ table.
Adverse events
We conducted a preliminary scoping search: no adverse events or
serious adverse events were reported in 20 physical activity or ex-
ercise training studies in people with ConHD. Adverse events are
classified as any untoward occurrence, which may not necessar-
ily be directly caused by the intervention (European Commission
2011). Expected adverse events are minor arrhythmia; illnesses;
muscle, ligament and tendon damage. We will also report serious
adverse events: these are classified as any occurrence that can result
in life-threatening situations, disability or death, or requires hos-
pitalisation of any duration (European Commission 2011). Ex-
pected serious adverse events are malignant cardiac arrhythmias
and myocardial infarctions. Due to the dearth of available data,
we will present all reported events (regardless of whether they were
considered to be ’adverse’ or ’serious adverse’ events) in the review
(by individual adverse event type) and in the ’Summary of find-
ings’ table (> 12months post intervention). This is because it is the
most relevant outcome encompassing patient-centred outcomes
and physical activity guideline development.
Search methods for identification of studies
Electronic searches
Wewill search the following databases: Cochrane Central Register
of ControlledTrials (CENTRAL) in theCochrane Library;MED-
LINE (Ovid); Embase (Ovid); BIOSIS Citation Index (Thomson
Reuters); Database of Abstracts of Reviews of Effects (DARE via
www.crd.york.ac.uk/CRDWeb/HomePage.asp); Cumulative In-
dex to Nursing and Allied Health Literature (CINAHL via EB-
SCOhost); Latin American and Caribbean Health Sciences Lit-
erature (LILACS via BIREME); Physiotherapy evidence database
(PEDro via www.pedro.fhs.usyd.edu.au/index.html); Allied and
Complementary Medicine Database (AMED via Ovid); and Web
of Science (Thomson Reuters).
We will draw up a systematic search strategy to identify relevant
randomised controlled studies without language or date restric-
tions. The preliminary search strategy for MEDLINE (Appendix
1) will be adapted across all other databases. We will apply the
Cochrane sensitivity-maximising RCT filter (Lefebvre 2011) to
MEDLINE (Ovid), and adaptations of it to the other databases,
except CENTRAL.
We will search for any ongoing trials in the following clinical trial
registers.
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1. www.ClinicalTrials.gov;
2. The World Health Organization (WHO) International
Clinical Trials Registry Platform ( ICTRP) ( apps.who.int/
trialsearch).
Searching other resources
We will search by hand the reference list of relevant reviews, ran-
domised andnon-randomised studies, and editorials for additional
studies. We will contact the main authors of studies and experts
in the field to ask for any missed, unreported or ongoing trials.
We will also search for any retraction statements and errata for
included studies.
Data collection and analysis
Selection of studies
Two review authors (CAW and CW) will independently screen
titles and abstracts for inclusion from all the potential trials we
identify from the search. We will then source full texts and both
review authors (CAW and CW) will independently read them to
confirm eligibility; or they will record their reasons for exclusion.
If there are any disagreements that cannot be rectified through
discussion, CAW and CWwill ask LL and RST to arbitrate. Once
complete, CAW and CWwill extract the data using a piloted data
collection sheet, if necessary linking multiple reports from the
same trial. CAW and CW will resolve any disagreement through
discussion or, if required, will consult both LL and RST. We will
record the selection process with a PRISMA flow diagram and
‘Characteristics of excluded studies’ table (Liberati 2009).
Data extraction and management
Initially, two authors (CAW and CW) will independently pilot a
data collection form for study characteristics and outcome data
for one of the included studies. The two review authors (CAW
and CW) will independently extract outcome data from included
studies.Wewill resolve disagreements by consensus or by involving
LL and RST. One review author will transfer data into the Review
Manager 5 file (Review Manager 2014); and a second author will
check that the data is entered correctly.
We will extract the following study characteristics.
1. Participants: N randomised, N lost to follow up, N
analysed, mean age (± range), gender, severity of condition*,
diagnostic criteria, inclusion criteria, and exclusion criteria.
2. Methods: study design, total duration of study, study
setting, date of study, withdrawals, number of study centres and
location.
3. Interventions: intervention (including the dose (frequency,
intensity and time) and the nature of the intervention),
comparison, and co-interventions.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for trial, and notable conflicts of interest of
trial authors.
*As ConHD is an incredibly varied and complex disease the sever-
ity of the condition will be classified using the Hoffman 2002
criteria as ‘mild’, ‘moderate’ or ‘severe’ (see Appendix 2 for further
information). We have chosen the Hoffman classification as it is
very inclusive and does not bias against individual intra-diagnosis
differences; it has since been adopted in the most recent guidelines
from the US Task Force for adult congenital heart disease (Warnes
2008). We will adopt diagnostic criteria most important for out-
comes related to activity and exercise participation (Budts 2013);
the five criteria are as follows.
1. Ventricular function and hypertrophy
2. Pulmonary artery pressure
3. Aortic dilation
4. Arrhythmia
5. Blood oxygen saturation at rest and exercise
Assessment of risk of bias in included studies
Two review authors will independently assess risk of bias for each
study using the recently revised ’Risk of bias in randomised trials
(RoB 2.0)’ tool (Higgins 2019).We will resolve any disagreements
by discussion or by involving another author.
Risk of bias will be assessed using the following Cochrane RoB
2.0 criteria (Higgins 2019).
1. Bias arising from the randomisation process
2. Bias due to deviations from intended interventions
3. Bias due to missing outcome data
4. Bias in measurement of the outcome
5. Bias in selection of the reported result
We will assess risk of bias in each domain. An algorithm (or de-
cision tree) using a series of signalling questions with the answers
(yes, probably yes, no information, probably no, no) will deter-
mine the risk of bias (low risk, some concerns and high risk). We
will include a text box alongside the questions and judgements to
provide supporting information for decisions.
Our analysis of bias due to deviations from intended interventions
will assess the effect of assignment to the intervention at baseline,
sometimes known as the ‘intention-to-treat effect’. We will min-
imise selective reporting, which could overestimate the effects of
an intervention, by contacting authors for unpublished data. We
will grade each potential source of bias as a ’low’, ’high’ or ’some
concerns’ and provide a quote from the study report together with
a justification for our judgement in the ‘Risk of bias’ table.We will
summarise the ‘Risk of bias’ judgements across different studies
for each of the domains listed. Where information on risk of bias
relates to unpublished data or correspondence with an author, we
will note this in the ‘Risk of bias’ table. When analysing treatment
effects, we will consider the risk of bias for the studies that con-
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tribute to that outcome.
Measures of treatment effect
We will analyse dichotomous data as risk ratios with 95% confi-
dence intervals and continuous data as mean difference with 95%
confidence intervals. For any outcomes which are measured by
studies in a variety of ways, we will either analyse these outcomes
separately or we will use the standardised mean difference (SMD)
with 95% confidence intervals as a summary statistic. We will en-
ter data presented as a scale with a consistent direction of effect.
We will narratively describe skewed data reported as medians and
interquartile ranges.
Unit of analysis issues
In accordance with Section 16.4 of the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011), we will aim to
include data from both periods of any cross-over trials identified,
assuming (i) there has been a wash-out period considered long
enough to reduce carry-over, (ii) no irreversible events such asmor-
tality have occurred, and (iii) appropriate statistical approaches
have been used. We will use multiple time points from individual
trials, and to define completely separate pooled analysis of out-
comes (e.g. HRQoL less than 6 months; HRQoL between 6 and
12 months etc.). This will avoid the situation where the same data
appears more than once in the same analysis. We will adjust cluster
RCTs’ sample sizes or standard errors using the methods outlined
in the Cochrane Handbook for Systematic Reviews of Interventions
using an estimate of the intracluster correlation co-efficient (ICC)
derived from the trial, from a similar trial or from a study of a
similar population. If we use ICCs from other sources, we will re-
port this result and conduct sensitivity analyses to investigate the
effect of variation in the ICC. If we have identified both cluster-
randomised trials and individually-randomised trials, we plan to
synthesise the relevant information. We will consider it reasonable
to combine the results from both if there is little heterogeneity
between the study designs and if we consider the interaction be-
tween the effect of intervention and the choice of randomisation
unit to be unlikely. We will also acknowledge heterogeneity in the
randomisation unit, and perform a subgroup analysis to investi-
gate the effects of the randomisation unit if necessary
Dealing with missing data
We will contact investigators or study sponsors to verify key study
characteristics and obtain missing numerical outcome data where
possible (for example when a study is identified as abstract only).
We will also use the Review Manager 5 calculator to calculate any
missing standard deviation data if there is sufficient data reported
(standard error or 95% CI) to allow us to calculate this (Review
Manager 2014).
Assessment of heterogeneity
We will explore heterogeneity amongst included studies qualita-
tively (by comparing the characteristics of included studies) and
quantitatively (using the Chi² test of heterogeneity and I² statis-
tic). We will use a threshold of I² greater than 50% (considered
to represent substantial heterogeneity (Deeks 2017) for both di-
chotomous and continuous outcomes to determine the statistical
model to be used for meta-analysis. We will employ a random-
effects model where there was formal evidence of statistical het-
erogeneity (i.e. Chi² test P value < 0.10 and I² statistic > 50%).
We will also explore any substantial heterogeneity by subgroup
analysis; and we will use visual inspection of the forest plots to
assess heterogeneity.
Assessment of reporting biases
If we are able to pool more than 10 trials, we will create and
examine a funnel plot and employ the Egger test to explore possible
small-study biases for the primary outcomes (Egger 1997).
Data synthesis
We will undertake meta-analyses only where this is meaningful,
i.e. if the treatments, participants and the underlying clinical ques-
tion are similar enough for pooling to make sense. We will ex-
press dichotomous outcomes for each comparison as risk ratios
with 95% CI. We will express continuous data as mean difference
with 95% CI; or, where an outcome is measured and reported in
more than one way, as SMD with 95% CI. We will enter data
presented as a scale with a consistent direction of effect. If meta-
analysis indicates that there is evidence of an outcome difference,
we will aim to calculate the associated number needed to treat (and
95% CI) for an additional beneficial or harmful outcome. Where
appropriate, we will pool data from each study using a fixed-effect
model, except where substantial heterogeneity exists. If possible,
we will pool the results for HRQoL using SMD.We will calculate
numbers needed to treat for all outcomes together with their 95%
CI. For outcomes where the meta-analysis indicates an effect of
the intervention we will use the random-effects model; and we will
also report the fixed-effect pooled estimate and 95%CI because of
the tendency of smaller trials, which are more susceptible to pub-
lication bias, to be over-weighted with a random-effects analysis
(Heran 2008a; Heran 2008b).
Wewill process data in accordance with theCochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). We will com-
plete data synthesis and analyses using ReviewManager 5 software
(ReviewManager 2014).Wewill conductmeta-regression analysis
using the “metareg” command in Stata version 14.2 (Stata 2015
[Computer program]).
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’Summary of findings’ table
Two reviewers will independently undertake GRADE analysis
using GRADEpro to grade the certainty of the available evi-
dence and therefore help inform decisions based on this evidence
(Schünemann 2017). We will use the five GRADE considerations
(study limitations, consistency of effect, imprecision, indirectness,
and publication bias) to assess the quality of a body of evidence as
it relates to the studies that contribute data to the meta-analyses
for the pre-specified outcomes. GRADEpro GDT will be used to
import data fromReviewManager 5 to create a ‘Summary of find-
ings’ table (Table 1). We will aim to create a ‘Summary of find-
ings’ table using the following outcomes: health-related quality
of life, maximal cardiorespiratory fitness, device-worn ‘objective’
measures of physical activity, hospital admissions, sub-maximal
CRF, muscular strength (grip strength), and adverse events. We
will use methods and recommendations described in Section 8.5
and Chapter 12 of the Cochrane Handbook for Systematic Reviews
of Interventions using GRADEpro software (Higgins 2011). We
will justify all decisions to downgrade the quality of studies using
footnotes and will include comments to aid readers’ understand-
ing of the review where necessary.
Long-term follow-up (> 12 months) is our follow-up period of
most interest because it is useful in influencing policy decisions.
Therefore, long-term follow-up will be included in the ’Summary
of findings’ table.
Subgroup analysis and investigation of heterogeneity
We anticipate length of follow-up to be a driver of intervention
effect, with the size of effect for some outcomes being related to
the length of the follow-up. We will therefore aim to stratify meta-
analysis of each outcome according to the length of trial duration:
i.e. ‘short-term’ follow-up (< 6 months); ‘medium-term’ follow-
up (6 to 12 months); and ‘long-term’ follow-up (more than 12
months). Wewill also aim to undertake univariate meta-regression
to explore heterogeneity and examine potential treatment effect
modifiers. We will aim to test the following hypotheses regard-
ing differences in the effect of exercise-based CR on health-related
quality of life, physical activity and exercise capacity across partic-
ular subgroups (Anderson 2016; Anderson 2017).
1. Type of intervention (physical activity or exercise only
versus multi-component intervention (categorical variable)).
2. ‘Dose’ of exercise intervention (dose = number of weeks of
exercise training × average number of sessions/week × average
duration of session in minutes) (dose 1000 units versus dose <
1000 units) (continuous variable).
3. Follow-up period (continuous variable).
4. Sample size (continuous variable).
5. Setting (home- or centre-based CR) (categorical variable).
6. Study location (continent) (categorical variable).
7. Mean age of participants (paediatrics and adults will be
analysed separately) (continuous variable).
8. Percentage of male participants (continuous variable).
Given the anticipated small ratio of trials to co-variates, we will
limit meta-regression to univariate analysis (Higgins 2011). Given
the anticipated small number of included studies, however, we
recognise that it would be unlikely that meta-regression or a strati-
fied meta-analysis will be possible. We will aim to extract results of
subgroup analyses, including participant-level subgroup analyses,
if reported by individual included studies; for example, if a trial
reports whether there was a difference in the effectiveness of CR
between males and females.
Sensitivity analysis
We will compare meta-analysis results of including all studies ver-
sus only including those studies we judge to have overall low risk
of bias (low risk in all domains).
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A D D I T I O N A L T A B L E S
Table 1. ’Summary of findings’ table
Physical activity and exercise interventions vs. control for the treatment of congenital heart disease at follow-up of more than 12
months
Patient or population: people with congenital heart disease
Setting: any setting (community, hospital/outpatient centre and at home)
Intervention: physical activity promotion or exercise training
Comparison: usual care















10Physical activity interventions for people with congenital heart disease (Protocol)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.


































*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect
of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the
effect, but there is a possibility that it is substantially different
Low certainty: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the
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Table 1. ’Summary of findings’ table (Continued)
effect
Very low certainty:We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the
estimate of effect
A P P E N D I C E S
Appendix 1. Preliminary MEDLINE (Ovid) search strategy
1 exp Exercise/ (175393)
2 Physical Fitness/ (26125)
3 exp Sports/ (169572)
4 Rehabilitation/ (17785)
5 Dance Therapy/ (319)
6 exp Exercise Therapy/ (45320)
7 Recreation Therapy/ (109)
8 Physical Exertion/ (55694)







16 ((lifestyle or life-style) adj5 activ$).tw. (5360)
17 ((lifestyle or life-style) adj5 physical$).tw. (4512)
18 (physical$ adj5 (fit$ or train$ or activ$ or endur$ or exert$ or perform* or inact*)).tw. (145418)
19 anaerobic.tw. (69805)
20 rehabilitat$.tw. (149916)
21 heart rate recovery.tw. (957)
22 danc*.tw. (6455)
23 (run* or jog*).tw. (175912)
24 or/1-23 (1011713)
25 exp Heart Defects, Congenital/ (143874)
26 exp Heart Diseases/cn [Congenital] (6434)
27 (heart adj2 (defect* or abnormal* or malform*)).tw. (14919)
28 (congenital adj2 (heart or cardiac or cardio*)).tw. (39864)
29 or/25-28 (164769)
30 24 and 29 (6071)
31 randomized controlled trial.pt. (477274)
32 controlled clinical trial.pt. (92948)
33 randomized.ab. (436415)
34 placebo.ab. (195896)
35 drug therapy.fs. (2088505)
36 randomly.ab. (306719)
37 trial.ab. (455958)
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38 groups.ab. (1887768)
39 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 (4390511)
40 exp animals/ not humans.sh. (4554611)
41 39 not 40 (3796835)
42 30 and 41 (1081)
Appendix 2. Severity classification in congenital heart disease
Severity of congenital heart disease is most often classified by lesion-specific data. While this approach is appropriate in most cases, it
must be stressed that severity is highly individual and should be judged by a physician using validated criteria (Budts 2013).
Mild ConHD
Mild ConHD is the least severe classification in our planned review. Patients with mild ConHD may be asymptomatic and have no
significant murmur. Some example lesions of mild ConHD are as follows.
• Bicuspid aortic valve (BAV)
• Small atrial septal defects (ASD)
• Small ventricular septal defects (VSD)
• Small patent ductus arteriosus
(PDA)
Moderate ConHD
Patients with moderate ConHD are likely to be symptomatic and the lesions will likely be identified in a clinical study. For example:
• mild or moderate aortic stenosis (AS) or aortic incompetence;
• moderate pulmonary stenosis (PS) or incompetence
;
• non-critical coarctation of the aorta;
• large atrial septal defect;
• complex forms of ventricular septal defect
.
Severe ConHD
This category includes complex conditions that usually require immediate medical intervention. Some example lesions are:
• dextro-transposition of the great arteries;
• tetralogy of fallot, including pulmonary atresia and absent pulmonary valve;
• hypoplastic right heart;
• tricuspid atresia
;
• pulmonary atresia with an intact ventricular septum;
• Ebstein anomaly;
• hypoplastic left heart;
◦ aortic atresia
◦ mitral atresia
• hypoplastic left heart;
◦ aortic atresia
◦ mitral atresia




• total anomalous pulmonary venous connection;
• large atrioventicular septal defect; large VSD; large PDA;
• severe AS and/or severe PS;
• critical coarctation of the aorta.
This framework has been adopted from the work of Hoffman 2002 and Warnes 2008.
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